Article
Hematology
Hailey Hill, Myra Robinson, Lauren Lu, Daniel Slaughter, Asim Amin, Kathryn Mileham, Jai N. Patel
Summary: This study evaluated the incidence and predictive factors of venous thromboembolism (VTE) in non-small cell lung cancer (NSCLC) patients receiving first-line therapies. The findings suggest that treatment type and smoking status can predict the time to VTE, with the highest incidence observed in patients receiving TTs and combination chemotherapy plus ICI.
THROMBOSIS RESEARCH
(2021)
Review
Pharmacology & Pharmacy
Xue-lin Zou, Wei-yong Chen, Guang-yan Zhang, Hua Ke, Qiu-hong Yang, Xiao-bo Li
Summary: This article discusses the potential adverse effects of thromboembolism in patients receiving immune checkpoint inhibitors, including high-risk factors, underlying mechanisms, incidence, prognosis, intervention, and treatment measures.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Hematology
Thure F. Overvad, Flemming Skjoth, Gregory Piazza, Simon Noble, Anne G. Ording, Torben B. Larsen, Peter B. Nielsen
Summary: The Khorana score can stratify patients with cancer treated with immune checkpoint inhibitors according to the 6-month risk of thromboembolic events. The risk of venous thromboembolism in this population was lower than in randomized thromboprophylaxis trials, which raises questions about the absolute benefit of routine primary thromboprophylaxis for these patients. Higher Khorana risk categories were also associated with a higher 6-month risk of arterial thrombosis and any thromboembolic events.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Oncology
Alexi Vasbinder, YeeAnn Chen, Adrien Procureur, Allison Gradone, Tariq U. Azam, Daniel Perry, Husam Shadid, Elizabeth Anderson, Tonimarie Catalan, Pennelope Blakely, Namratha Nelapudi, Mohamad Fardous, Marie C. Bretagne, Sarah K. Adie, Kristen T. Pogue, Monika Leja, Sarah Yentz, Bryan Schneider, Leslie A. Fecher, Christopher D. Lao, Joe-Elie Salem, Salim S. Hayek
Summary: This study aimed to determine the biomarker trends and their association with the incidence and outcomes of immune checkpoint inhibitor (ICI) myocarditis. The results showed that patients with ICI myocarditis had elevated levels of AST, ALT, and CPK. An increase in noncardiac biomarkers, especially CPK, during ICI treatment should prompt further evaluation for ICI myocarditis.
JACC: CARDIOONCOLOGY
(2022)
Article
Oncology
Tyler C. Haddad, Songzhu Zhao, Mingjia Li, Sandip H. Patel, Andrew Johns, Madison Grogan, Gabriella Lopez, Abdul Miah, Lai Wei, Gabriel Tinoco, Brian Riesenberg, Zihai Li, Alexa Meara, Erin M. Bertino, Kari Kendra, Gregory Otterson, Carolyn J. Presley, Dwight H. Owen
Summary: This study retrospectively reviewed cancer patients treated with ICI between 2011 and 2017, finding that 8.6% of patients developed severe thrombocytopenia, with severe irTCP associated with lower survival rates. The incidence of irTCP was lowest among those receiving PD-1/L1 monotherapy.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Jingyi Gong, Zsofia D. Drobni, Raza M. Alvi, Sean P. Murphy, Ryan J. Sullivan, Sarah E. Hartmann, Hannah K. Gilman, Hang Lee, Leyre Zubiri, Vineet K. Raghu, Rebecca S. Karp-Leaf, Amna Zafar, Daniel A. Zlotoff, Matthew J. Frigault, Kerry L. Reynolds, Tomas G. Neilan
Summary: The study found that the risk of VTE was 7.4% at 6 months and 13.8% at 1 year after starting an ICI, with a significantly increased rate of VTE. Factors such as age, medical history, and underlying diseases can predict the risk of VTE in patients receiving ICIs.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Miho Kono, Malek Shatila, Guofan Xu, Yang Lu, Antony Mathew, Wasay Mohajir, Krishnavathana Varatharajalu, Wei Qiao, Anusha S. Thomas, Yinghong Wang
Summary: This retrospective study explored the relationship between obesity and immune checkpoint inhibitor-induced immune-related adverse events (irAEs). The findings showed that lower body mass index (BMI) was associated with a more severe disease course. Obesity did not significantly alter the course of irAEs or impact overall survival. Importantly, the study supported the use of BMI as an indicator of adiposity in cancer patients.
Article
Cardiac & Cardiovascular Systems
Stancu Alma, Debourdeau Eloi, Vazquez Lea, Coussirou Julie, Matagne Valerie, Grassi Pierre, Werner Hilgers, Girard Philippe, Zammit Christine, Debourdeau Philippe
Summary: Lung cancer patients treated with immune-checkpoint inhibitors (ICIs) have an increased risk of venous thromboembolism (VTE), which negatively impacts survival. The current VTE prediction models do not perform well in this population.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2022)
Article
Critical Care Medicine
William T. Atchley, Carolina Alvarez, Shruti Saxena-Beem, Todd A. Schwartz, Rumey C. Ishizawar, Kunal P. Patel, M. Patricia Rivera
Summary: In this retrospective case-control study, it was found that immune checkpoint inhibitor-related pneumonitis (ICI-P) was more common and severe in lung cancer patients than previously reported, and was independently associated with several chronic pulmonary diseases.
Article
Hematology
Florian Moik, Cihan Ay
Summary: Patients with cancer receiving targeted anti-cancer therapies and immunotherapy have an increased risk of venous and arterial thromboembolism. These treatments have greatly improved patient care but also contribute to prothrombotic effects and increased risk of blood clots.
THROMBOSIS RESEARCH
(2022)
Article
Critical Care Medicine
Ruben J. Eck, Lisa Hulshof, Renske Wiersema, Chris H. L. Thio, Bart Hiemstra, Niels C. Gritters van den Oever, Reinold O. B. Gans, Iwan C. C. van der Horst, Karina Meijer, Frederik Keus
Summary: This study aimed to describe the prevalence, incidence, prognostic factors, and outcomes of venous thromboembolism in critically ill patients receiving thrombosis prophylaxis. The development of PE-LDVT but not NLDVT was associated with increased mortality. Prognostic factors for developing PE-LDVT or NLDVT despite prophylaxis can be identified at ICU admission.
Review
Oncology
Tzu-Fei Wang, Marc Carrier
Summary: Immune checkpoint inhibitors have become an integral part of cancer treatment, but they carry the risk of thrombosis, which can lead to various complications. Recent studies have shown that C-reactive protein dynamics may serve as a biomarker for thrombosis. Furthermore, early findings suggest that factor Xa inhibitors used for cancer-associated thrombosis may have potential synergistic antitumor effects when combined with ICIs.
Review
Pharmacology & Pharmacy
Yuji Shibata, Shuji Murakami, Terufumi Kato
Summary: The development of immune checkpoint inhibitors has revolutionized the treatment of various cancers, leading to the emergence of checkpoint inhibitor pneumonitis (CIP) as a potential challenge for clinicians. Clinical trials investigating combination therapies with ICIs have shown slightly higher rates of CIP compared to monotherapies, highlighting the importance of proper management of immune-related adverse events to maximize treatment efficacy.
EXPERT OPINION ON DRUG SAFETY
(2021)
Article
Surgery
Qiang Guo, Jichun Zhao, Xiaojiong Du, Hankui Hu, Bin Huang
Summary: The study found that age, recurrence, and vascular resection are independent risk factors associated with VTE in patients undergoing retroperitoneal tumor surgery. VTE was also linked to inferior overall survival in these patients.
INTERNATIONAL JOURNAL OF SURGERY
(2023)
Article
Multidisciplinary Sciences
Ying Li, Matthew Brendel, Ning Wu, Wenzhen Ge, Hao Zhang, Petra Rietschel, Ruben G. W. Quek, Jean-Francois Pouliot, Fei Wang, James Harnett
Summary: This study applied a machine learning model to predict survival outcomes of patients with non-small cell lung cancer treated with immune checkpoint inhibitors. The model showed good performance in predicting overall survival and progression-free survival, and identified important predictors for these outcomes. These findings contribute to a better understanding of treatment heterogeneity and can inform treatment decisions.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Andrew B. Lassman, Stephanie L. Pugh, Tony J. C. Wang, Kenneth Aldape, Hui K. Gan, Matthias Preusser, Michael A. Vogelbaum, Erik P. Sulman, Minhee Won, Peixin Zhang, Golnaz Moazami, Marian S. Macsai, Mark R. Gilbert, Earle E. Bain, Vincent Blot, Peter J. Ansell, Suvajit Samanta, Madan G. Kundu, Terri S. Armstrong, Jeffrey S. Wefel, Clemens Seidel, Filip Y. de Vos, Sigmund Hsu, Andres F. Cardona, Giuseppe Lombardi, Dmitry Bentsion, Richard A. Peterson, Craig Gedye, Veronique Bourg, Antje Wick, Walter J. Curran, Minesh P. Mehta
Summary: The use of depatux-m in newly diagnosed glioblastomas (GBMs) with epidermal growth factor receptor gene amplification (EGFR-amp) did not improve overall survival (OS), but showed a longer progression-free survival. There were safety risks associated with the treatment, leading to treatment discontinuation for some patients.
Article
Oncology
Khe Hoang-Xuan, Martina Deckert, Andres J. M. Ferreri, Julia Furtner, Jaime Gallego Perez-Larraya, Roger Henriksson, Andreas F. Hottinger, Benjamin Kasenda, Florence Lefranc, Alexander Lossos, Catherine McBain, Matthias Preusser, Patrick Roth, Roberta Ruda, Uwe Schlegel, Riccardo Soffietti, Carole Soussain, Martin J. B. Taphoorn, Valerie Touitou, Michael Weller, Jacoline E. C. Bromberg
Summary: The management of primary central nervous system lymphoma (PCNSL) is a controversial topic in neuro-oncology. The European Association of Neuro-Oncology (EANO) formed a multidisciplinary task force to update the evidence-based guidelines and include immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly.
Article
Oncology
Emilie Le Rhun, Felix Boakye Oppong, Martin van den Bent, Wolfgang Wick, Alba A. Brandes, Martin J. B. Taphoorn, Michael Platten, Ahmed Idbaih, Paul M. Clement, Matthias Preusser, Vassilis Golfinopoulos, Thierry Gorlia, Michael Weller
Summary: This study retrospectively analyzed the incidence of lomustine-induced thrombocytopenia and its impact on treatment exposure and survival in patients with recurrent glioblastoma. The results showed that thrombocytopenia induced by lomustine is a major limitation to adequate exposure to lomustine chemotherapy and is associated with inferior progression-free survival, particularly in patients with MGMT promoter-methylated tumors.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Maximilian J. Mair, Anna S. Berghoff, Priscilla K. Brastianos, Matthias Preusser
Summary: Meningiomas are the most frequently diagnosed intracranial neoplasms and surgical resection is the common treatment method. However, there is limited research on pharmacotherapy for meningiomas.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Oncology
David Capper, Guido Reifenberger, Pim J. French, Leonille Schweizer, Michael Weller, Mehdi Touat, Simone P. Niclou, Philipp Euskirchen, Christine Haberler, Monika E. Hegi, Sebastian Brandner, Emilie Le Rhun, Roberta Ruda, Marc Sanson, Ghazaleh Tabatabai, Felix Sahm, Patrick Y. Wen, Pieter Wesseling, Matthias Preusser, Martin J. van den Bent
Summary: The mainstay of treatment for adult patients with gliomas, glioneuronal and neuronal tumors consists of combinations of surgery, radiotherapy, and chemotherapy. For many systemic cancers, targeted treatments are a part of the standard of care, however, the predictive significance of most of these targets in central nervous system (CNS) tumors remains less well-studied.
Editorial Material
Oncology
Matthias Preusser, Martin J. van den Bent
Article
Oncology
Elisabeth S. Bergen, Alexander Friedrich, Peter Scherleitner, Pedro Ferreira, Barbara Kiesel, Georg Widhalm, Barbara Kiesewetter, Franziska Eckert, Gerald W. Prager, Matthias Preusser, Anna S. Berghoff
Summary: The prognosis of brain metastases from hepatopancreatobiliary tumors is very limited, with poor outcomes. Negative prognostic factors identified include performance status, age, and leptomeningeal carcinomatosis.
CLINICAL & EXPERIMENTAL METASTASIS
(2023)
Article
Oncology
Ladislaia Wolff, Ariane Steindl, Petar Popov, Karin Dieckmann, Brigitte Gatterbauer, Georg Widhalm, Anna Sophie Berghoff, Matthias Preusser, Markus Raderer, Barbara Kiesewetter
Summary: In this study, brain metastases (BM) in patients with thyroid cancer (TC) were found to be rare, with follicular and papillary thyroid carcinomas being the most common types. Most of the patients presented with symptomatic single lesions, and some patients were able to achieve long-term survival with local therapy.
CLINICAL & EXPERIMENTAL METASTASIS
(2023)
Article
Medicine, General & Internal
Gerald Gartlehner, Eva Schernhammer, Sigurd F. Lax, Matthias Preusser, Herbert Bachler, Harald Tietzer, Maria Kletecka-Pulker, Helga Turnher, Uwe Siebert
Summary: Colorectal cancer screening in Austria is currently opportunistic and the Austrian National Committee for Cancer Screening has developed evidence-based recommendations for an organized nationwide screening program. The recommendations suggest that adults aged 45-75 should undergo either a 10-year screening colonoscopy or biennial fecal immunochemical tests. Screening decisions for individuals aged 65 and older should be based on their overall health, prior screening history, and preferences.
WIENER KLINISCHE WOCHENSCHRIFT
(2023)
Article
Oncology
Maximilian J. Mair, Agnieszka Maj-Hes, Alina Nussbaumer-Proell, Rainer Puhr, Agnieszka Christenheit, Marlene Troch, Hannah C. Puhr, Angelika M. Starzer, Ariane Steindl, Sabine Eberl, Helmuth Haslacher, Thomas Perkmann, Christoph Minichsdorfer, Gerald W. Prager, Wolfgang W. Lamm, Anna S. Berghoff, Barbara Kiesewetter, Markus Zeitlinger, Matthias Preusser, Markus Raderer
Summary: This study aimed to investigate the preventive effect of azithromycin on COVID-19 infection in cancer patients, but due to low acceptance and low incidence of infection, the study was prematurely closed. Nevertheless, azithromycin had a favorable side effect profile in cancer patients.
INFECTIOUS AGENTS AND CANCER
(2023)
Review
Oncology
Hannah Christina Puhr, Thorsten J. Reiter, Matthias Preusser, Gerald W. Prager, Ayseguel Ilhan-Mutlu
Summary: Gastroesophageal cancer is a devastating disease with poor survival outcomes. Advances in immunotherapy and targeted therapies are being explored to improve patient management and outcomes. This review summarizes the progress in these treatments for localized gastric, gastroesophageal junction, and esophageal tumors, as well as ongoing promising clinical trials.
Correction
Biochemistry & Molecular Biology
John M. Kirkwood, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M. Meniawy, Paolo A. Ascierto, Alexander M. Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, Georgina V. Long
Article
Biochemistry & Molecular Biology
John Kirkwood, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M. Meniawy, Paolo A. Ascierto, Alexander M. Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, Georgina V. Long
Summary: Nivolumab is an effective and well-tolerated adjuvant treatment for patients with resected stage IIB/C melanoma.
Correction
Medicine, General & Internal
Gerald Gartlehner, Eva Schernhammer, Sigurd F. Lax, Matthias Preusser, Herbert Bachler, Harald Titzer, Maria Kletecka-Pulker, Helga Turnher, Uwe Siebert
WIENER KLINISCHE WOCHENSCHRIFT
(2023)
Article
Hematology
Stephan Nopp, Florian Moik, Simon Kraler, Cornelia Englisch, Matthias Preusser, Arnold von Eckardstein, Ingrid Pabinger, Thomas F. Luescher, Cihan Ay
Summary: GDF-15 is strongly associated with survival in cancer patients, independent of established risk factors. Although an association was identified with ATE and VTE in univariable analysis, GDF-15 was not independently associated with these outcomes and failed to improve established VTE prediction models.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)